DEST Insider Trading

Insider Ownership Percentage: 24.65%
Insider Buying (Last 12 Months): GBX 0
Insider Selling (Last 12 Months): GBX 0

Destiny Pharma Insider Trading History Chart

This chart shows the insider buying and selling history at Destiny Pharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Destiny Pharma Share Price & Price History

Current Price: GBX 10.25
Price Change: +0.30 (1.20%)
As of 06/21/2024 01:00 AM ET

This chart shows the closing price history over time for DEST up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Destiny Pharma Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/25/2023Nick RodgersInsiderBuy49,477GBX 31£15,337.87
2/27/2023Nick RodgersInsiderBuy20,000GBX 34£6,800
9/27/2021Nick RodgersInsiderBuy2,100£119.80£251,580
See Full Table

SEC Filings (Institutional Ownership Changes) for Destiny Pharma (LON:DEST)

27.33% of Destiny Pharma stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Destiny Pharma logo
Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of novel medicines to prevent serious infections in the United Kingdom. The company is involved in developing NTCD-M3 that is in Phase II clinical trial for the prevention of recurrent Clostridioides diffcile infections; XF-73 Nasal, which is in Phase II clinical trial for the prevention of post-surgical staphylococcal infection; and XF-73 Dermal that is in preclinical stage for the treatment of skin infections of antibiotic resistant bacteria, as well as superficial skin infections of antibiotic resistant bacteria. It also develops SPOR-COV, biotherapeutic product, which is in preclinical stage for the prevention of COVID-19 and other viral respiratory infections; and XF Drugs Research/Biofilms that is in preclinical stage for the treatment of antibiotic resistant biofilm and bacterial aggregate associated infections. In addition, the company is involved in the development of XF drugs for the treatment of respiratory, dermal, oral and ocular infections. Destiny Pharma plc has collaboration agreements with China Medical System Holdings Limited; SporeGen Limited; Sebela Pharmaceuticals; the University of Southampton; Aston University; the University of Sheffield; National Biofilms Innovation Centre; National Institute of Allergy and Infectious Diseases; Cystic Fibrosis Foundation; Cardiff University; and Tianjin Medical University. The company was incorporated in 1996 and is based in Brighton, the United Kingdom.
Read More on Destiny Pharma

Today's Range

Now: GBX 10.25
Low: 10
High: 10.25

50 Day Range

MA: GBX 16.17
Low: 10.25
High: 23

52 Week Range

Now: GBX 10.25
Low: 9.55
High: 84

Volume

12,750 shs

Average Volume

481,550 shs

Market Capitalization

£9.77 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.31

Who are the company insiders with the largest holdings of Destiny Pharma?

Destiny Pharma's top insider investors include:
  1. Nick Rodgers (Insider)
Learn More about top insider investors at Destiny Pharma.